A human surfactant peptide-elastase inhibitor construct as a treatment for emphysema
- 8 June 2010
- journal article
- research article
- Published by Proceedings of the National Academy of Sciences in Proceedings of the National Academy of Sciences of the United States of America
- Vol. 107 (23), 10661-10666
- https://doi.org/10.1073/pnas.1001349107
Abstract
Two million Americans suffer from pulmonary emphysema, costing $2.5 billion/year and contributing to 100,000 deaths/year. Emphysema is thought to result from an imbalance between elastase and endogenous inhibitors of elastase, leading to tissue destruction and a loss of alveoli. Decades of research have still not resulted in an effective treatment other than stopping cigarette smoking, a highly addictive behavior. On the basis of our previous work, we hypothesize that small molecule inhibitors of human neutrophil elastase are ineffective because of rapid clearance from the lungs. To develop a long-acting elastase inhibitor with a lung pharmacodynamic profile that has minimal immunogenicity, we covalently linked an elastase inhibitor, similar to a trifluoro inhibitor that was used in clinical trials, to a 25-amino-acid fragment of human surfactant peptide B. We used this construct to prevent human neutrophil elastase-induced emphysema in a rodent model. The elastase inhibitor alone, although in a 70-fold molar excess to elastase in a mixture with <0.6% residual elastase activity, provided no protection from elastase-induced emphysema. Covalently combining an endogenous peptide from the target organ with a synthetic small molecule inhibitor is a unique way of endowing an active compound with the pharmacodynamic profile needed to create in vivo efficacy.Keywords
This publication has 42 references indexed in Scilit:
- Low Rates of Pseudomonas aeruginosa Misidentification in Isolates from Cystic Fibrosis PatientsJournal of Clinical Microbiology, 2009
- Functional selectivity of EGF family peptide growth factors: Implications for cancerPharmacology & Therapeutics, 2008
- Novel long‐acting bronchodilators for COPD and asthmaBritish Journal of Pharmacology, 2008
- Review: Surfactant respiratory therapy using Surfaxin/sinapultideTherapeutic Advances in Respiratory Disease, 2008
- Sleep-Predominant Lowering of Ambulatory Blood Pressure by Bedtime Inhalation of a Novel Muscarinic M3 Receptor Antagonist: A New “Bronchoantihypertensive” Strategy Targeting the Lung in Hypertension with Chronic Obstructive Pulmonary DiseaseHypertension Research, 2008
- Systemic Delivery of Drugs to Humans via InhalationJournal of Aerosol Medicine, 2006
- Recent advances in MMP inhibitor designCancer and Metastasis Reviews, 2006
- A Polymer-Bound Elastase Inhibitor Is Effective in Preventing Human Neutrophil Elastase-Induced EmphysemaAnnals of the New York Academy of Sciences, 1991
- Biochemistry and Pharmacology of ICI 200,880, a Synthetic Peptide Inhibitor of Human Neutrophil ElastaseAnnals of the New York Academy of Sciences, 1991
- An 18-Month Study of the Effects on Hamster Lungs of Intratracheally Administered Human Neutrophil ElastaseExperimental Lung Research, 1988